CVRx (NASDAQ: CVRX) reported Q2 2026 revenue of $15.7 million, up 16% year over year, while basic and diluted net loss per share improved to $0.53 from $0.57. U.S. growth and a higher gross margin narrowed the company’s net loss, but weaker European sales, lower-than-planned sales capacity, productivity issues, and a payer challenge weighed on the updated outlook.

Core Earnings Data

U.S. sales remained the main growth driver, lifting total revenue by $2.1 million from the prior-year quarter. Gross profit increased faster than revenue as cost of goods sold declined, raising gross margin by three percentage points.

The higher gross profit more than offset a modest increase in operating expenses, narrowing both operating and net losses. Cash use nevertheless increased from the year-ago period.

Cash use in the table is the company’s combined operating-and-investing measure, rather than a separately reported free cash flow figure.

Business and Geographic Performance

U.S. revenue increased 21% as CVRx added territories and accounts and benefited from greater physician and patient awareness of Barostim. Implant volume also rose, while the number of active U.S. implanting centers reached 258.

Europe moved in the opposite direction. Revenue declined 31% and implant units fell from 61 to 40, partially offsetting the U.S. expansion.

Active centers and territory counts are as of June 30 in each respective year. CVRx defines an active implanting center as a customer that completed at least one commercial heart-failure implant during the preceding 12 months.

Profitability, Cash Flow, and Balance Sheet

Cost of goods sold declined to $2.0 million from $2.1 million even as revenue increased, supporting the improvement in gross margin. Gross profit rose by approximately $2.3 million, compared with an increase of about $0.9 million in total operating expenses, which explains most of the narrower operating loss.

R&D expense increased 27% to $3.1 million, driven by $0.6 million of additional headcount costs and $0.1 million of higher clinical trial spending. SG&A expense increased only 1% to $23.6 million: higher stock-based compensation and legal costs were partly offset by lower advertising and travel expenses.

CVRx ended June with $64.6 million in cash and cash equivalents, down from $75.7 million at December 31, 2025. Over the same period, long-term debt increased to $58.6 million from $49.5 million. The additional term-loan borrowing contributed to higher interest expense, while lower cash balances reduced interest income.

Inventory increased to $13.0 million from $12.2 million at the end of 2025. Combined operating and investing cash use was $8.9 million during the quarter, compared with $8.0 million a year earlier.

Reimbursement Gains Have Not Removed Sales Execution Pressure

Humana introduced a Medicare Advantage coverage policy for Barostim effective May 1, 2026. The policy covers patients meeting the therapy’s current FDA-approved indication and patients participating in the BENEFIT-HF trial. Humana serves approximately 5.2 million Medicare Advantage members across 46 states.

This followed two first-quarter reimbursement developments: the transition to Category I CPT codes and CMS approval of Category B investigational device exemption coverage for BENEFIT-HF patients. However, management said its updated outlook reflects fewer sales territories than anticipated, lower sales force productivity, and a prolonged challenge with one of the company’s largest payers.

The distinction is important: CVRx expanded its U.S. territory count from 47 to 56 and made measurable reimbursement progress, but those advances have not yet translated into the level of near-term commercial performance management had planned.

Earnings Guidance

CVRx now expects full-year revenue of $58.0 million to $60.0 million, gross margin of 86% to 87%, and operating expenses of $99.0 million to $101.0 million. The company also expects Q3 revenue of $13.5 million to $14.5 million, which is $1.2 million to $2.2 million below the Q2 result and indicates sequential moderation.

The supplied information does not include the company’s previous numerical guidance ranges, so the size of any revision cannot be quantified.

Recent Insider Transactions

The supplied six-month summary reports 518,725 shares categorized as purchases and 16,017 shares sold, producing net purchases of 502,708 shares across 21 transactions. The latest 10 itemized records consist of seven director stock awards and three executive sales; the awards should not be treated as open-market purchases.

The supplied records do not provide the number of shares associated with the seven June stock awards. These transactions alone do not establish management’s view of CVRx’s valuation or future performance.

Risks Investors Need to Watch

• Sales capacity and productivity: U.S. territories increased year over year but remained below management’s plan, while lower sales force productivity contributed to the updated outlook.
• Payer access: Humana’s policy is an important reimbursement step, but the prolonged issue with one of CVRx’s largest payers could continue to affect patient access and revenue conversion.
• Persistent losses and cash use: CVRx recorded a $14.0 million quarterly net loss and used $8.9 million in operating and investing activities. Continued cash use would reduce the company’s financial flexibility.
• Higher debt and interest costs: Long-term debt rose by approximately $9.1 million from year-end, contributing to higher interest expense as cash balances declined.
• European contraction: European revenue fell 31% and units declined about 34%, creating a geographic drag on otherwise growing U.S. operations.

Summary

CVRx’s Q2 2026 results showed continued U.S. adoption of Barostim, a higher gross margin, and narrower operating and net losses. Those improvements were tempered by declining European sales, increased cash use, and commercial execution issues that are constraining the near-term outlook despite meaningful reimbursement progress. The main items to monitor are sales force productivity, resolution of the payer challenge, conversion of broader coverage into implants, and the company’s cash and debt trajectory.

Find out more